Hoth Therapeutics (HOTH) Stock Analysis: AI Score & Alternative Data
Demand signals are heating up for Hoth Therapeutics
Is Hoth Therapeutics a buy right now? The alternative data says hold. This HOTH stock analysis is built on the 25+ alternative data signals AltIndex tracks on Hoth Therapeutics every day — hiring, web traffic, sentiment, social reach — rolled into an AI Score of 46/100: a Hold. The stock trades at $1.36 with a $26M market cap.
The data leans positive over the past 90 days — web traffic up 38.8% to 4K monthly visits — but the move hasn’t been broad enough to lift HOTH into buy territory yet.
HOTH’s broader alt-data profile also covers headcount (9 employees, according to LinkedIn), X followers (159), and sentiment (100/100). Every signal links to its own page with full history, the HOTH technical analysis covers RSI, moving averages, and support and resistance, and the full table of everything AltIndex tracks on HOTH is just below.
Hoth Therapeutics AI Stock Analysis
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for unmet medical needs in various disease areas, including dermatology, oncology, and infectious diseases. The company's pipeline includes several promising candidates, targeting conditions with significant market potential and underserved populations.
Analysis generated July 1, 2026.
Recent Hoth Therapeutics Stock Alerts
|
Hoth Therapeutics | May 28 Reddit mentions are up by 57300% in the last 24h. |
|
Hoth Therapeutics | May 27 Price is up by 21.4% in the last 24h. |
|
Hoth Therapeutics | May 21 Price is up by 6.7% in the last 24h. |
|
Hoth Therapeutics | May 19 Price is down by -10% in the last 24h. |
Hoth Therapeutics Alternative Data
| Alternative Data | Value | 3m Change | Trend |
|---|---|---|---|
| Webpage Traffic | 4K | 38.8% | |
| LinkedIn Employees | 9 | N/A | |
| Employee Recommend | 0 | N/A | |
| Business Outlook | 0 | N/A | |
| Sentiment | 100 | 0% | |
| Reddit Mentions | 0 | N/A | |
| X Mentions | 1 | N/A | |
| Stocktwits Mentions | 14 | 0% | |
| News Mentions | 0 | N/A | |
| Stocktwits Subscribers | 12K | N/A | |
| X Followers | 159 | N/A |
About Hoth Therapeutics (HOTH)
Hoth Therapeutics, Inc., a biopharmaceutical company, is focused on developing therapies for dermatological disorders. The company is headquartered in New York, New York.
| Price | $1.36 |
| Target Price | $387.74 |
| Volume | 63,420,177 |
| Market Cap | $26M |
| Year Range | $1 – $2 |
| Dividend Yield | 0% |
| PE Ratio | — |
| Analyst Rating | 38% buy |
| Industry | Biotechnology |
Latest Hoth Therapeutics News
View more → |
Hoth Therapeutics Becomes Rocket One Inc. (Nasdaq: RKTO), Targeting the Space Economy with Next-Generation Nanomagnetic AI Chip Technology and Ultra-Low-Power, Radiation-Tolerant Computing for Space and Defense ApplicationsMay 27 - PRNewswire |
|
Hoth Therapeutics Awarded U.S. Patent for Cancer-Fighting HT-KIT Oncology PlatformMay 26 - PRNewswire |
|
AI Chip Energy Efficiency: Hoth Therapeutics Restructures as Rocket One Inc. to Enter the AI Semiconductor Infrastructure Market with Acquisition of Exclusive Rights to Next Generation AI Semiconductor Acceleration Technology Built on Non-Volatile Nanomagnetic Semiconductor ArchitectureMay 19 - PRNewswire |
EXCLUSIVE: Hoth Therapeutics To Rebrand To Pursue AI Chip TechnologiesMay 19 - Yahoo Entertainment |
|
|
Hoth Therapeutics Secures European Authorization in Spain for HT-001 Phase 2a Trial as Interim Data Show Strong Efficacy in Cancer PatientsMay 5 - PRNewswire |
Hoth Therapeutics Earnings & Financial Performance
View all earnings →Hoth Therapeutics Insider Trading Activity
View all →| Knie Robb filed to sell 58,131 shares at $0.0. Aug 16 '24 |
Hoth Therapeutics Congress Trading
View all →| Politician | Filing Date | Type | Size |
|---|---|---|---|
| No congress trades on file. | |||
Stocks Similar to Hoth Therapeutics
See all →| Company | Price | Market Cap | AI Score | |
|---|---|---|---|---|
 |
China Pharma HoldingCPHI |
$0.57 11.0% | $26M | 51 |
 |
BioXcel TherapeuticsBTAI |
$0.82 2.7% | $26M | 38 |
 |
NeuroSense TherapeuticsNRSN |
$0.72 1.6% | $26M | 42 |
 |
Akari TherapeuticsAKTX |
$13.89 5.5% | $25M | 48 |
 |
Kala PharmaceuticalsKALA |
$1.30 3.7% | $25M | 44 |
Explore Hoth Therapeutics Data
Frequently Asked Questions: Hoth Therapeutics (HOTH)
Hoth Therapeutics has an AltIndex AI Score of 46/100 (Hold). The score reflects mixed alternative data signals. All investments carry risk.
46/100. The AI Score combines 25+ alternative data signals including job postings, employee sentiment, social media, web traffic, and financials. Scores above 60 = buy, 40–59 = hold, below 40 = sell. Updated daily.
Currently, the price of one share of Hoth Therapeutics (HOTH) stock is $1.36 with a market cap of $26M.
As of today, Hoth Therapeutics’s PE (Price to Earnings) ratio is —.
View the latest Hoth Therapeutics insider transactions to see recent buying and selling activity by company executives and directors.
Check the Hoth Therapeutics congress trading page for the latest disclosed trades by U.S. senators and representatives.
AltIndex tracks 25+ signals including job postings, web traffic, employee sentiment, Reddit mentions, Stocktwits activity, insider transactions, congressional trades, Google Trends, app downloads, and more.
The HOTH stock price chart above shows Hoth Therapeutics’s performance over time alongside its AI Score. Investors can identify patterns, trends, and potential support or resistance levels. View the full Hoth Therapeutics technical analysis for RSI, moving averages, and more.
See the stocks similar to Hoth Therapeutics section on this page for companies in the same industry ranked by market cap and AI Score.
